04 · Five things to know · 02

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Must read

Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer. In 61 patients, 60.7% had a confirmed response and median progression-free survival was 12.8 months. Another single-arm result. The randomized test against chemotherapy alone, RASolute 303, has not read out.

From the edition's At a glance, as printed.

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know